Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/313"
| Predicate | Value (sorted: none) |
|---|
| rdf:type |
|
| rdf:type |
|
| rdfs:label |
"evidence_1350"
|
| ?:Evidence_type |
|
| ?:Evidence_enzyme_system |
|
| dc:creator |
|
| dc:date |
|
| ?:content |
"Route of administration: oral
polymorphic enzyme: NO
study duration: 4 days
population: 7 male, 3 female
ages:19-29
description:
Two randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with simvastatin (study I) and one with pravastatin (study II). In both studies, 10 healthy volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of simvastatin (study I) or pravastatin (study II). Serum concentrations of simvastatin, simvastatin acid, pravastatin, HMG-CoA reductase inhibitors, itraconazole, and hydroxyitraconazole were determined. RESULTS: In study I, itraconazole increased the peak serum concentrations (Cmax) and the areas under the serum concentration-time curve [AUC(0-infinity)] of simvastatin and simvastatin acid at least tenfold (p < 0.001)."
|
| rdfs:seeAlso |
|
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ simvastatin_is_not_substrate_of_cyp3a4, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1350 }
Context graph
